1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Teva Exits Japanese Generics With Plan To Sell Local Business

Firm Registers Impairment Charge Of Almost $600m As Unit Is Classified As Held-For-Sale

 
• By Dave Wallace

Teva is putting its Japanese generics business up for sale, in an exit from the country’s generics market that has led the Israeli firm to register a substantial impairment charge in Q1.

Yen symbol in front of doorway with red background
Teva is facing an exit from its Japanese generics business • Source: Shutterstock

Teva is exiting the Japanese generics market, putting its local generics business up for sale in a process that the Israeli generics giant expects to close within the next 12 months.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.